CNM Au 8
Alternative Names: Clean-surfaced gold nanocrystals; CNM-Au8; Gold nanocrystal suspension; Nanocrystalline goldLatest Information Update: 08 Aug 2024
At a glance
- Originator Clene Nanomedicine
- Class Antiparkinsonians; Eye disorder therapies; Heavy metals
- Mechanism of Action Energy metabolism stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Amyotrophic lateral sclerosis
- Phase II/III Multiple sclerosis
- Phase II Optic nerve disorders; Parkinson's disease
- Preclinical Rett syndrome
Most Recent Events
- 06 Aug 2024 Clene plans a Type C meeting with the US FDA to discuss an accelerated approval regulatory pathway in the third quarter of 2024
- 16 Jul 2024 Clene Nanomedicine plans interaction with FDA to receive feedback on the potential path to submission of a new drug application (NDA) for CNM-Au8 in third quarter of 2024
- 11 Jul 2024 Clene Nanomedicine plans to submit a briefing book by July 13 to the USFDA in advance of a granted Type C interaction